Study Number:

**Study Gender:** 

**PWG Approval Date:** 

Version:

I01: Animal Removal Summary Test Compound: N-Butylbenzenesulfonamide CAS Number: 3622-84-2

I10482

Female See web page for date of PWG Approval v1.0.9 Date Report Requested: 11/04/2020 Time Report Requested: 12:49:16 Lab: Burleson Research Technologies

Female: SRBC									
Phase	Removal Reasons		Treatment Groups (ppm)						
		0	313	625	1250	2500	5000	50 mg/kg CPS	Total
SD	Scheduled Removal (Terminal)	8	8	8	8	8	8	8	56

Female: KLH									
Phase	Removal Reasons		Treatment Groups (ppm)						
		0	313	625	1250	2500	5000	50 mg/kg CPS	Total
SD	Scheduled Removal (Terminal)	8	8	8	8	8	8	8	56

Female: Immunophenotyping									
Phase	Removal Reasons	Treatment Groups (ppm)							
		0	313	625	1250	2500	5000	50 mg/kg CPS	Total
SD	Scheduled Removal (Terminal)	8	8	8	8	8	8	8	56

Female: CTL									
Phase	Removal Reasons	Treatment Groups (ppm)							
		0	313	625	1250	2500	5000	50 mg/kg CPS	Total
SD	Euthanized Moribund	0	0	0	0	0	0	1	1
SD	Scheduled Removal (Terminal)	8	8	8	8	8	8	7	55

Female: Immunopath									
Phase	Removal Reasons	Treatment Groups (ppm)							
		0	313	625	1250	2500	5000	50 mg/kg CPS	Total
SD	Scheduled Removal (Terminal)	8	8	8	8	8	8	8	56

LEGEND

SD – Study Day CPS = Cyclophosphamide I01: Animal Removal Summary Test Compound: N-Butylbenzenesulfonamide CAS Number: 3622-84-2 Date Report Requested: 11/04/2020 Time Report Requested: 12:49:16 Lab: Burleson Research Technologies

\*\* END OF REPORT \*\*